

World Journal of *Clinical Cases*

World J Clin Cases 2022 May 16; 10(14): 4327-4712



Contents

Thrice Monthly Volume 10 Number 14 May 16, 2022

OPINION REVIEW

- 4327 Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
Najeeb H, Yasmin F, Surani S

MINIREVIEWS

- 4334 Practical insights into chronic management of hepatic Wilson's disease
Lynch EN, Campani C, Innocenti T, Dragoni G, Forte P, Galli A
- 4348 Adipose-derived stem cells in the treatment of hepatobiliary diseases and sepsis
Satilmis B, Cicek GS, Cicek E, Akbulut S, Sahin TT, Yilmaz S

ORIGINAL ARTICLE

Clinical and Translational Research

- 4357 Learning curve for a surgeon in robotic pancreaticoduodenectomy through a "G"-shaped approach: A cumulative sum analysis
Wei ZG, Liang CJ, Du Y, Zhang YP, Liu Y
- 4368 Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer
Wu C, Feng ML, Jiao TW, Sun MJ

Case Control Study

- 4380 Significance of preoperative peripheral blood neutrophil-lymphocyte ratio in predicting postoperative survival in patients with multiple myeloma bone disease
Xu ZY, Yao XC, Shi XJ, Du XR

Retrospective Study

- 4395 Association between depression and malnutrition in pulmonary tuberculosis patients: A cross-sectional study
Fang XE, Chen DP, Tang LL, Mao YJ
- 4404 Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China
Yin MY, Xi LT, Liu L, Zhu JZ, Qian LJ, Xu CF
- 4414 Evaluation of short- and medium-term efficacy and complications of ultrasound-guided ablation for small liver cancer
Zhong H, Hu R, Jiang YS

- 4425** Hematopoiesis reconstitution and anti-tumor effectiveness of Pai-Neng-Da capsule in acute leukemia patients with haploidentical hematopoietic stem cell transplantation

Yuan JJ, Lu Y, Cao JJ, Pei RZ, Gao RL

- 4436** Oral and maxillofacial pain as the first sign of metastasis of an occult primary tumour: A fifteen-year retrospective study

Shan S, Liu S, Yang ZY, Wang TM, Lin ZT, Feng YL, Pakezhati S, Huang XF, Zhang L, Sun GW

- 4446** Reduced serum high-density lipoprotein cholesterol levels and aberrantly expressed cholesterol metabolism genes in colorectal cancer

Tao JH, Wang XT, Yuan W, Chen JN, Wang ZJ, Ma YB, Zhao FQ, Zhang LY, Ma J, Liu Q

Observational Study

- 4460** Correlation of pressure gradient in three hepatic veins with portal pressure gradient

Wang HY, Song QK, Yue ZD, Wang L, Fan ZH, Wu YF, Dong CB, Zhang Y, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ

- 4470** Multi-slice spiral computed tomography in diagnosing unstable pelvic fractures in elderly and effect of less invasive stabilization

Huang JG, Zhang ZY, Li L, Liu GB, Li X

SYSTEMATIC REVIEWS

- 4480** Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020

Yang J, Liu HX, Su YY, Liang ZS, Rao HY

CASE REPORT

- 4494** Bow hunter's syndrome successfully treated with a posterior surgical decompression approach: A case report and review of literature

Orlandi N, Cavallieri F, Grisendi I, Romano A, Ghadirpour R, Napoli M, Moratti C, Zanichelli M, Pascarella R, Valzania F, Zedde M

- 4502** Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report

Huguenot M, Bruhm AC, Essig M

- 4509** Cutaneous mucosa-associated lymphoid tissue lymphoma complicating Sjögren's syndrome: A case report and review of literature

Liu Y, Zhu J, Huang YH, Zhang QR, Zhao LL, Yu RH

- 4519** Plexiform neurofibroma of the cauda equina with follow-up of 10 years: A case report

Chomanskis Z, Juskys R, Cepkus S, Dulko J, Hendrixson V, Ruksenas O, Rocka S

- 4528** Mixed porokeratosis with a novel mevalonate kinase gene mutation: A case report

Xu HJ, Wen GD

- 4535** Isolated pancreatic injury caused by abdominal massage: A case report

Sun BL, Zhang LL, Yu WM, Tuo HF

- 4541** Bronchiolar adenoma with unusual presentation: Two case reports
Du Y, Wang ZY, Zheng Z, Li YX, Wang XY, Du R
- 4550** Periodontal-orthodontic interdisciplinary management of a “periodontally hopeless” maxillary central incisor with severe mobility: A case report and review of literature
Jiang K, Jiang LS, Li HX, Lei L
- 4563** Anesthesia management for cesarean section in a pregnant woman with odontogenic infection: A case report
Ren YL, Ma YS
- 4569** Convulsive-like movements as the first symptom of basilar artery occlusive brainstem infarction: A case report
Wang TL, Wu G, Liu SZ
- 4574** Globe luxation may prevent myopia in a child: A case report
Li Q, Xu YX
- 4580** Computer tomography-guided negative pressure drainage treatment of intrathoracic esophagojejunal anastomotic leakage: A case report
Jiang ZY, Tao GQ, Zhu YF
- 4586** Primary or metastatic lung cancer? Sebaceous carcinoma of the thigh: A case report
Wei XL, Liu Q, Zeng QL, Zhou H
- 4594** Perianesthesia emergency repair of a cut endotracheal tube’s inflatable tube: A case report
Wang TT, Wang J, Sun TT, Hou YT, Lu Y, Chen SG
- 4601** Diagnosis of cytomegalovirus encephalitis using metagenomic next-generation sequencing of blood and cerebrospinal fluid: A case report
Xu CQ, Chen XL, Zhang DS, Wang JW, Yuan H, Chen WF, Xia H, Zhang ZY, Peng FH
- 4608** Primary sigmoid squamous cell carcinoma with liver metastasis: A case report
Li XY, Teng G, Zhao X, Zhu CM
- 4617** Acute recurrent cerebral infarction caused by moyamoya disease complicated with adenomyosis: A case report
Zhang S, Zhao LM, Xue BQ, Liang H, Guo GC, Liu Y, Wu RY, Li CY
- 4625** Serum-negative Sjogren's syndrome with minimal lesion nephropathy as the initial presentation: A case report
Li CY, Li YM, Tian M
- 4632** Successful individualized endodontic treatment of severely curved root canals in a mandibular second molar: A case report
Xu LJ, Zhang JY, Huang ZH, Wang XZ

- 4640** Successful treatment in one myelodysplastic syndrome patient with primary thrombocytopenia and secondary deep vein thrombosis: A case report
Liu WB, Ma JX, Tong HX
- 4648** Diagnosis of an extremely rare case of malignant adenomyoepithelioma in pleomorphic adenoma: A case report
Zhang WT, Wang YB, Ang Y, Wang HZ, Li YX
- 4654** Management about intravesical histological transformation of prostatic mucinous carcinoma after radical prostatectomy: A case report
Bai SJ, Ma L, Luo M, Xu H, Yang L
- 4661** Hepatopulmonary metastases from papillary thyroid microcarcinoma: A case report
Yang CY, Chen XW, Tang D, Yang WJ, Mi XX, Shi JP, Du WD
- 4669** PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
Zhang HQ, Huang CZ, Wu JY, Wang ZL, Shao Y, Fu Z
- 4676** Cutaneous metastasis from esophageal squamous cell carcinoma: A case report
Zhang RY, Zhu SJ, Xue P, He SQ
- 4684** Rare pattern of Maisonneuve fracture: A case report
Zhao B, Li N, Cao HB, Wang GX, He JQ
- 4691** Suprasellar cistern tuberculoma presenting as unilateral ocular motility disorder and ptosis: A case report
Zhao BB, Tian C, Fu LJ, Zhang XB
- 4698** Development of plasma cell dyscrasias in a patient with chronic myeloid leukemia: A case report
Zhang N, Jiang TD, Yi SH
- 4704** Ovarian growing teratoma syndrome with multiple metastases in the abdominal cavity and liver: A case report
Hu X, Jia Z, Zhou LX, Kakongoma N

LETTER TO THE EDITOR

- 4709** Perfectionism and mental health problems: Limitations and directions for future research
Nazari N

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Jamir Pitton Rissardo, MD, Academic Research, Adjunct Associate Professor, Research Associate, Department of Medicine, Federal University of Santa Maria, Santa Maria 97105110, Brazil. jamirrissardo@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2021 Edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJCC as 1.337; IF without journal self cites: 1.301; 5-year IF: 1.742; Journal Citation Indicator: 0.33; Ranking: 119 among 169 journals in medicine, general and internal; and Quartile category: Q3. The WJCC's CiteScore for 2020 is 0.8 and Scopus CiteScore rank 2020: General Medicine is 493/793.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yin, Production Department Director: Xu Guo, Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

May 16, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020

Jia Yang, Hui-Xin Liu, Ying-Ying Su, Zhi-Sheng Liang, Hui-Ying Rao

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Kao JT, Taiwan; Wang H, China

Received: November 8, 2021

Peer-review started: November 8, 2021

First decision: February 14, 2022

Revised: February 28, 2022

Accepted: March 25, 2022

Article in press: March 25, 2022

Published online: May 16, 2022



Jia Yang, Hui-Ying Rao, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Beijing 100044, China

Hui-Xin Liu, Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing 100044, China

Ying-Ying Su, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361000, Fujian Province, China

Zhi-Sheng Liang, Department of Global Health, School of Public Health, Peking University, Beijing 100044, China

Corresponding author: Hui-Ying Rao, MD, PhD, Chief Doctor, Professor, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China. rao.huiying@163.com

Abstract

BACKGROUND

Hepatitis C virus (HCV) causes a large number of infections worldwide. New infections seem to be increasing according to a report of the World Health Organization in 2015. Although direct-acting antivirals are quite effective for most genotypes of the HCV, some genotypes fail to respond. Therefore, the trend of genotype distribution is vital to better control the development of this infection.

AIM

To analyze the distribution and trends of the HCV genotype before and after the emergence of direct-acting antivirals in China.

METHODS

We searched all literature published in five electronic databases-China National Knowledge Infrastructure, Wan Fang Data, VIP Chinese Journal Database, Chinese Biomedical Literature Service System, and PubMed-from January 1, 2010 to December 31, 2020. The search strategy combined medical subject headings and free-text terms, including "hepatitis C virus" or "HCV" and "genotype" or "subtype" and "China" or "Chinese". Additional relevant articles were searched by manual selection. Data were extracted to build a database. All of the data were totaled according to regions, periods, routes of transmission, and sexes. The

percentages in various stratifications were calculated.

RESULTS

There were 76110 samples from 30 provinces included in the study. Genotype 1 (G1) accounted for 58.2% of cases nationwide, followed by G2, G6, G3b, G3a, unclassified and mixed infections (17.5%, 7.8%, 6.4%, 4.9%, 1.8%, and 1.2%, respectively). The constitution of genotype varied among different regions, with G6 and G3b being more common in the south and southwest, respectively (28.1%, 15.4%). The past ten years have witnessed a decrease in G1 and G2 and an increase in G3 and G6 in almost all regions. The drug-use population had the most abundant genotypes, with G6 ranking first (33.3%), followed by G1 and G3b (23.4%, 18.5%).

CONCLUSION

G3 and G6 pose a new challenge for HCV infection. This study revealed the distribution of HCV genotypes in China over the past 10 years, providing information for HCV management strategies.

Key Words: Hepacivirus; Genotype; China; Drug users; Direct-acting antiviral; Hepatitis C virus

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This article comprehensively included the literature published in recent years and reflects a picture of the genotype constitution of hepatitis C virus (HCV), showing increases in genotype 3 and genotype 6 owing to an increase in intravenous drug users, providing the prevention direction for future HCV control.

Citation: Yang J, Liu HX, Su YY, Liang ZS, Rao HY. Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. *World J Clin Cases* 2022; 10(14): 4480-4493

URL: <https://www.wjgnet.com/2307-8960/full/v10/i14/4480.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i14.4480>

INTRODUCTION

According to the World Health Organization (WHO), there were 71 million people with chronic hepatitis C virus (HCV) infection in 2015 worldwide, and approximately 1.75 million new infections occurred in 2015. Unsafe health care procedures and injection drug use are responsible for most new HCV infections[1]. It is estimated that China has approximately 10 million HCV infections[2]. A report from the Ministry of Health of China found that new HCV infections rose from 70681 to 242897 between 2006 and 2017[3]. Left untreated, 20% or more of chronic HCV infections will develop into cirrhosis or hepatocellular carcinoma (HCC)[4]. As a result, in May 2016, the World Health Assembly endorsed the Global Health Sector Strategy (GHSS) for 2016-2021 on viral hepatitis, proposing to eliminate viral hepatitis as a public health threat by 2030[5].

HCV is a single-stranded RNA that can easily mutate. It is classified into seven confirmed genotypes and 67 subtypes[6]. Treatment is likely to be the most effective available option right now. The revolution in HCV therapy has been attributed to direct-acting antivirals (DAAs). The sustained virologic response rate has reached more than 90% of the main known genotypes and subtypes. However, the pangenotype regimen is not as effective in some of the genotypes, especially genotype 3b (G3b) with cirrhosis[2]. Limited data have shown that the SVR rate in G3b patients without cirrhosis is 96% and is 50% in cirrhosis patients. Genotype 1 (G1) and genotype 3 (G3) HCV infections are related to an increased risk for cirrhosis and HCC [7]. G3b also progresses more rapidly than G1[8]. Therefore, the Chinese Guidelines for HCV in 2019 recommend genotyping before treatment in regions with more than a 5% prevalence of G3b[2]. For treatment failure, genotyping is also needed to differentiate between relapse and reinfection[9]. HCV genotypes and subtypes remain the cornerstones in the management of HCV infection, even in the era of DAAs[10].

In addition, the geographic distribution of HCV genotypes offers information about the origin of infection and possible transmission routes[11]. The changes in distribution over time could provide information to guide monitoring and improve prevention for policy-makers. In this way, measures could be put into effect to avoid new and repeated infections.

However, there have been only six articles about China HCV distribution nationwide, four of which were cross-sectional studies[12-15] and two of which were literature reviews[3,16]. The most recent cross-sectional study and review were both from 2017. Most of these studies only included a few years or started in the 1990s. DAA officially came onto the market in 2017 in China. No studies of the HCV

genotype distribution over the past 10 years have been published, although the first generation of DAA was approved by the FDA in 2011[5], swiftly evolving into the fourth generation currently. Our study included the genotype data of Chinese individuals from 2010 to 2020 and explored the evolution of HCV genotypes over time and regions in the different risk groups and both sexes.

MATERIALS AND METHODS

Search strategy

We searched all of the literature published in five electronic databases-China National Knowledge Infrastructure (CNKI), Wanfang Data, VIP Chinese Journal Database (CQVIP), Chinese Biomedical Literature Service System (SinoMed), and PubMed-from January 1, 2010 to December 31, 2020. The search strategy combined medical subject headings and free-text terms including “hepatitis C virus” or “HCV” and “genotype” or “subtype” and “China” or “Chinese”. To acquire more comprehensive data, additional relevant articles were searched by manual selection from the references of published literature.

Selection criteria

The inclusion criteria were as follows: (1) Studies reporting the distribution of HCV genotypes and with specific numbers of genotypes; (2) The sample sizes of genotypes equal to or greater than 50; (3) The population included being Chinese; and (4) Studies adopting the Simmond genotype nomenclature system. Studies were excluded if they met the following exclusion criteria: (1) Redundant publication; (2) Human immunodeficiency virus (HIV)/HCV or HBV/HCV coinfection; (3) Studies with no specific data of genotypes, no exact inclusion time or not in the required period; (4) Clinical trials; (5) Sample size of genotypes less than 50; and (6) Non-Chinese populations.

Data extraction

Data extraction from the included studies contained the following information: Year of publication, name of the first author, sampling time, risk group, province, route of transmission, HCV genotyping region, genotyping method and method of HCV RNA detection, ethnic group, sample size, numbers of subtypes in all populations and each sex population.

Data analysis

The database was built in Microsoft Excel software, version 2019, and the 30 provinces are divided into seven geographical regions according to the National Bureau of Statistics of China and other relevant studies[3]: North, South, Central, Northwest, Northeast, Southwest, and Southeast. The regions to which samples belong were determined by the areas where the infection was diagnosed. The periods were divided into two parts according to the sampling year: The 2010-2015 period and the 2016-2020 period. Although DAAs were not approved until 2017 in China, many patients had access to generic drugs from India before 2017. For the studies included, HCV genotypes were totaled by different classifications: Regions, periods, routes of transmission, and sexes. Then, we calculated the percentage in various stratifications; thus, the compositions of each genotype and subtype were obtained. Graphs were built using Excel software, version 2019, and R software, version 4.0.3.

RESULTS

Literature screening

The criteria of screening identified 5480 articles from the five electronic databases (CNKI = 1878, Wanfang = 1782, CQVIP = 560, SinoMed = 1146, PubMed = 114), and another eight articles were identified from the references of the articles above. The literature screening procedure is shown in Figure 1.


The characteristics of the included studies

The overall data are extracted from 170 articles from five databases from January 1, 2010 to December 31, 2020, involving 76110 samples from 30 provinces on the Chinese mainland. These samples included injecting drug users (IDUs), volunteer blood donors, formerly paid plasma donors (FDPs), sexually infected individuals, hemodialysis patients, a mother-to-child transmission group, an invasive operation group, and other unknown risk groups. The ten-year samples were classified into 2010 to 2015 and 2016 to 2020, comprising 30466 and 7607 samples in each period, respectively. The results are shown in Table 1. All of the studies included adopted the Simmond system. The methods used for genotyping varied from real-time fluorescent polymerase chain reaction (PCR), Tag Man probe hybridization, and Sanger sequencing to nested RT-PCR and pyrosequencing gene chip assays. The most common regions used for determining GT and subtypes were Core/E1 and NS5b, which are currently considered to be

Table 1 Included articles and samples in every province and region from 2010 to 2020

Region	Province	Number of articles included			Sample size		
		2010-2015	2016-2020	Subtotal	2010-2015	2016-2020	Subtotal
Northwest	Shaanxi	3	1	6	3799	268	4930
	Gansu	5	1	6	298	112	699
	Ningxia	3	0	3	183	0	183
	Qinghai	2	0	4	150	0	562
	Xinjiang	5	2	12	1373	747	7694
	Subtotal	18	4	31	5803	1127	14068
Central	Hunan	4	0	5	925	0	1877
	Hubei	10	1	14	2602	84	2686
	Henan	7	0	8	840	0	1134
	Subtotal	21	1	27	4367	84	5697
North	Beijing	5	0	7	2175	0	13222
	Hebei	4	1	6	385	284	1427
	Shanxi	1	2	3	36	278	314
	Tianjin	3	0	3	777	0	777
	Inner Mongolia	4	0	6	1299	0	2203
	subtotal	17	3	25	4672	562	17943
South	Guangdong	9	3	13	1553	946	5421
	Guangxi	7	0	8	785	0	1629
	Hainan	2	1	5	283	128	1666
	subtotal	18	4	26	2621	1074	8716
Northeast	Liaoning	3	1	5	436	100	627
	Jilin	2	0	2	616	0	616
	Heilongjiang	3	0	3	0	360	360
	subtotal	8	1	10	1052	460	1603
Southwest	Yunnan	7	3	13	538	2183	2861
	Guizhou	6	1	9	926	359	2528
	Sichuan	10	5	18	3372	1664	11243
	Chongqing	3	0	3	993	0	993
	subtotal	26	9	43	5829	4206	17625
East	Shandong	6	0	7	923	0	1371
	Jiangsu	11	0	13	3805	0	4708
	Anhui	2	0	5	245	0	746
	Zhejiang	4	1	7	644	94	1619
	Fujian	2	0	5	147	0	638
	Shanghai	3	0	3	324	0	324
	Jiangxi	1	0	2	34	0	1052
	subtotal	29	1	42	6122	94	10458
Total ¹		137	23	204	30466	7607	76110

¹Data involving Hongkong, Macao, and Taiwan were lacking.



DOI: 10.12998/wjcc.v10.i14.4480 Copyright ©The Author(s) 2022.

Figure 1 The procedure of literature research and selection. CNKI: China National Knowledge Infrastructure; WanFang: Wan Fang Data; CQVIP: VIP Chinese Journal Database; SinoMed: Chinese Biomedical Literature Service System; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus.

the gold standard for HCV genotyping[17,18].

The genotype distribution of different regions

G1 accounted for 58.2% of all HCV infections, while G2 continued to follow G1 as the second major genotype nationwide, accounting for up to 18.4%. G3 altogether ranked as the third most predominant genotype, with 11.4%, and subtype 3b surpassed 3a (6.4% *vs* 4.9%). G6 was less common than G3 but exceeded 3a and 3b, causing 7.8% of the infections. Mixed infection, unclassified genotype, and other genotypes (for example, genotypes 4 and 5) accounted for 1.2%, 1.8%, and 0.7% of the total infections, respectively.

In the Northeast, G1 and G2 were the two most popular genotypes, with both of them accounting for more than eighty percent of all genotypes, and the proportion of G2 in this area was 40.8%, ranking the highest in seven regions, compared with 4.9% to 31.7% of other regions. The South is the only area where G1 constituted less than 50%, and the second-most common was G6 rather than G2, accounting for almost 30%, while G3b, G3a, G2 were less than 10%. The predominant genotype of the other five regions was G1, accounting for 55% to 62.5% in each area. In the north and northwest, apart from the unidentified ones and other genotypes, G3a, G3b, and G6 followed the majority G1 and G2 in order. However, in the central and eastern regions, G6 ranked third, G3b ranked fourth, and G3a ranked fifth. The structure of the genotype in South and Southwest China was quite different from that in other parts of China. The second most predominant genotype was G6 and G3b, with G3 and G6 altogether explaining 34.1% and 42.8% of all HCV infections, respectively. Mixed infection was more commonly seen in East, South, and Central China, with rates of 3.1%, 2.4%, and 2%, respectively, which are less than the 1% in other parts of the nation, as depicted in Figure 2A.




Figure 2 The hepatitis C virus genotype distribution by region and time. A: Hepatitis C virus (HCV) genotype distribution in seven regions in China; B: Comparison of the composition ratio of the HCV genotype between 2010 and 2020.

The time trend of the composition ratio of the HCV genotype

From 2010 to 2015, G1 accounted for 56.1% of the HCV infections on the Chinese mainland, while G2 and G6 followed as the second and third genotypes with 20.5% and 7.46%, respectively. G3a, G3b, and mixed genotype ranked as the fourth and fifth highest infections, and the unidentified type and other genotypes were the last two ones. However, from 2016 to 2020, as G1 remained the most popular genotype, G3a, G3b, G6, and unidentified genotypes increased, especially dramatically for G3b and the

unclassified genotype. In this period, G3b rose to the third genotype with 9%. These changes are shown in [Figure 2B](#).

As the genotype distribution varied from area to area, the time trend of genotype distribution in the seven regions was also different. Except for the North, the proportion of genotype 1 in the other six areas all decreased from 2010-2015 to 2016-2020. The greatest decline was seen in the south at 13.1%, followed by the southwest at 11.1%. The proportion of G2 increased by 0.6% in the southwest, while other areas all decreased significantly. Mixed infections decreased in all regions other than the northwest. Compared with the mostly declining trend of G1 and G2, G3a, G3b, and G6 displayed the opposite tendency. G3b and G6 decreased only in the North, whereas G3a, G3b and G6 increased in all the other parts of China, with the greatest increases of G3a in the Northwest (7.3%), G3b in the Central (12.5%), and G6 in the South (12.8%), as shown in [Figure 3](#).

Composition ratio of HCV genotypes in different routes of transmission

The composition ratio of HCV genotypes in different risk populations was distinctly different, as shown in [Figure 4A](#). G1 accounted for the majority of the population of paid blood donor (PBD), blood transfusion or hemodialysis (BT or HD), and mother-to-child (MTC) transmissions. In these three populations, mixed infection was the second most predominant infection among paid blood donors, while G2 ranked second in the other two populations. The sex and invasive operation (IO) groups shared almost the same genotype composition except that G6 was higher and G3b was lower in the invasive operation group than in the sex group. The genotype distribution among drug users was quite different from all of the other risk groups. G6 ranked first, G1 and G3b ranked second and third, respectively, and G3a ranked fourth. G6, G3a, and G3b had larger proportions among drug users, sex, and invasive operation groups than other risk populations.

The time trend also varied in the various risk groups, as revealed by [Figure 4B](#). There were no included studies from 2016-2020 in the PBD and IO groups. The distribution rarely changed between the two periods in the DU group. However, in the BT or HD populations, G1 and G2 showed obvious decreases, while G6 and 3b increased at the same time, especially G6. In contrast, in the sex group, G1, G2, and G6 all decreased, whereas the mixed infection rate increased dramatically. The MTC group had the simplest composition, with only three subtypes. As time went on, G2 increased while G1 and G6 decreased.

Composition ratio of HCV genotype in men and women

G1 and G2 were the two major genotypes in both sexes, except that G1 constituted a larger proportion in men than in women (61.8% *vs* 46.3%). In addition, women had more G2 and G3a and less G3b and G6 than men. Regarding the changes over time, the two populations also showed discrepancies. G1 decreased while G2 increased from 2010-2015 to 2016-2020 period and G2 became the majority of the female group in 2016-2020 with 39.7% instead of G1 with 29.7%. At the same time, G1 and G2 in the male group dropped. G3a, G3b, and G6 increased dramatically in both sexes, and the growth was even greater in men. In terms of mixed infections, they decreased in men and increased in women. The changes are demonstrated in [Figure 5](#).

DISCUSSION

The WHO estimated that 399000 people had died from cirrhosis or HCC[6]. A clinical trial demonstrated that a 12-wk pangenotypic regimen based on a Chinese population achieved 100%, 100%, 95%, 76% and 99% SVR rates in genotypes 1a, 1b, 2, 3a, 3b and 6[19], respectively. G1 is more likely to clear spontaneously than other genotypes[20]. Studies have found that patients with cirrhosis and ongoing HCV infection of G3 had an increased risk of fibrosis progression and HCC compared with other subtypes[21,22]. Studies published about HCV genotypes obviously decreased from 2016 to 2020, compared with those published from 2010 to 2015. However, the Southwest still had a large number of studies, possibly due to the large proportion of G3 in this area and the less ideal effectiveness of treatment for it.

At the whole-nation level, G1 remained the most common in the last ten years (the vast majority of cases were G1b), and G2 was the second most popular. G3 remained the third most prevalent, showing a tendency toward catching up to G2. G6 followed G3; the mixed infection reached 1.2%, and other genotypes were less than 1%, in line with previous studies[12,14,23-25].

G1 remained the preponderant strain in all regions, accounting for more than 60% in Central and East, although its proportion decreased significantly. G2 was more frequent in northern China. Similar observations were made in a 1540-patient study[12]. G2a was closely associated with blood transfusions and selling of blood before 1997[26]. HCV genotypes changed distinctly after 1993 as the transmission of blood transfusions decreased[14]. G3a and G3b appeared to be concentrated in the southwest, and G6a was confined to the south in that study. However, G3a and G3b were also prevalent in the South, and G6 was not as common in the Central region, probably because of the economic development and migration flows in these three adjacent zones, driven by work, education, and transferring routes of





Figure 3 Hepatitis C virus genotypes between 2010 and 2020 in seven regions. A: Comparison of the composition ratio of hepatitis C virus (HCV) genotypes between 2010 and 2020 in seven regions; B: Changes in HCV genotype distribution between 2010 and 2020 in seven regions.

transmission[27]. The unique composition of the southwest and south could be a result of their special geographic locations or caused by illegal drug transactions[14]. G3 and G6 spread from here to distant locations[3], resulting in the increases of G3 and G6 in other regions.

A multicenter, large-sample study reported that the Han Chinese population before 2012 had a relatively simple genotype constitution, with G1 dominating, G6 rarely seen, and G3 Less common[15]. Du *et al*[3] found that G1b decreased consistently from 72% through 63.8% to 54%, while G2a fell mildly from 16.2% to 15.4%. In contrast, G3a, G3b and G6a increased from 0.2%, 0.3% and 0.1%, respectively, to 5.4%, 7.1% and 7.5%, respectively, before and after 2000. Our study depicted the same trend over the past 10 years; G1 tended to continue to drop[3,16,25,28], and G2 decreased steadily. Simultaneously, G3a, G3b and G6 grew from 4.1%, 5.3% and 7.3% to 6.1%, 9.0% and 8.5%, respectively.


G1 declined in all regions except in the North. G2 decreased sharply in all regions but increased in the southwest, perhaps because selling blood was prevalent in central and northern areas in the 1990s[26]. From 1993, anti-HCV was screened in all blood donors, and HCV RNA was screened in them from 2015. Most of the remaining HCV infections with G1 and G2 had histories of blood transfusion before 1993 since they are older than G3 infected people[2,29]. G3 increased in all areas. G3b and G6 underwent the same increase apart from a slight decrease in the North. Interestingly, G6a replaced G2a as the second most prevalent subtype during 2001-2009 and continued to increase thereafter[3,30], reaching as high as



DOI: 10.12998/wjcc.v10.i14.4480 Copyright ©The Author(s) 2022.

Figure 4 Hepatitis C virus genotypes in different transmission routes. A: The composition ratio of hepatitis C virus (HCV) genotypes in different routes of transmission; B: The changes in the composition ratio of HCV genotypes in different routes of transmission from 2010 to 2020. DU: Drug users; PBD: Paid blood donors, BT or HD: Blood transfusion or hemodialysis; MTC: Mother-to-child transmission; IO: Invasive operations, including tattoos, piercing, dental treatment, pedicure, and other invasive medical operation.

36.8% in the South during 2016-2020 in our study. G6 increased over time in Guangdong and spread from there to other parts of China[27]. Guangdong was responsible for one-sixth of all drug users in China at the time of 2015. New drug users are still increasing, with an estimated more than 75000 new drug users in 2018[31]. The other parts outside the south have also seen increases in G6. The South might be responsible for this increase with the origin of spreading owing to socioeconomic development. In addition, the higher viral load of G6a compared with other genotypes is also a cause of the higher infection rate[32]. The same story occurred in G3b in the southwest. Phylogeographic analysis indicated that G3b migrated from Yunnan to Guangdong and then was transmitted to other



DOI: 10.12998/wjcc.v10.i14.4480 Copyright ©The Author(s) 2022.

Figure 5 Changes in hepatitis C virus genotypes in men and women. A: Distribution of hepatitis C virus (HCV) genotypes in men and women; B: The time trends of HCV genotype proportions in men and women.

regions[31]. Furthermore, a poor response to DAAs also poses challenges to G3b elimination.

The mixed strain increased in the northwest and decreased in other regions. Mixed infections became more common, possibly owing to the increasing number of drug users, coverage of hemodialysis, population mobility, and advancement of detection methods[16].

Although G1 was the most prevalent in all risk groups, its share in the DU group was the lowest, in accordance with a previous study[3]. G2 is no longer the second most regular subtype in the various risk groups, except MTC and BT or HD populations, surpassed by G6 in DUs, as well as IO and mixed infection in PBD and by G3b in the sex group. The constitution of the PBD population in our study was quite different from that in previous studies, likely as a result of the Blood Donation Law in 1998. Illegal blood donation was forbidden, and voluntary blood donation was advocated for. The invasive operation group included higher proportions of G3 and G6, as observed in a multicenter study[14], and had similar distributions to the sex group. Transmission by IDU was more commonly seen in southern and western China, and G3 and G6 were more frequent in this group[27,33-35]. According to the phylogenetic analysis and risk factor study, G6a and G3b were more related to injecting drugs, and G3b could originate from Yunnan Province pertaining to the southwest[28,31,35]. G3a was more likely to spread by sex rather than by injecting drugs, according to an HIV/HCV coinfection study[36]. Although clean drug injection equipment is currently available, the proportion of genotypes barely changed over these ten years, and the share of G3 and G6 in the whole country continued to increase. A study regarding IDU in 2012 in Yunnan Province revealed that G6 increased while 3b and 1b decreased in the last five years before 2012[35]. A WHO desk review in 2019 found that less than half of countries valued the necessary interventions for people who inject drugs[37]. Nevertheless, in the whole population of south and southwest China, G6 and G3b rose dramatically, indicating spread from IDU to the general

population. Therefore, the reuse of contaminated syringes should be prevented, especially in the south and southwest, to reduce the transmission of G3 and G6[14]. Moreover, screening and treating of patients with HCV infection in this population are also essential to preclude spread to the general population.

In contrast to a nationwide study showing that G1b and G2a constituted a larger proportion of women than men and that 3a, 3b, and 6a exhibited the opposite[13], G1b, G3b and G6 accounted for a larger proportion in men than women in our study. From 2010 to 2020, G6 accounted for 6% of men compared with 4.5% of women, in line with a blood volunteer study[30]. However, G6 in women surpassed that in men in 2016-2020, likely because of the decrease in G1. In addition, according to a meta-analysis, female drug addicts are increasing, and approximately 80% of them are engaging in sex work[37].

The main limitation of our study is that it was a literature review study based on published studies, and publication bias is inevitable. Nevertheless, our research contained as many as seventy thousand samples, well depicting a whole picture of the HCV distribution over the last ten years, the associated data of which have been lacking. Another limitation is that some of the samples were from patients in hospitals, which might not reflect the situation of the general population. However, HCV is a very silent disease without significant manifestations in the early phase of infection. It is theoretically impractical to detect all infections. Furthermore, our study merely totaled all the samples and calculated the proportions of the genotypes, and the exact prevalence of each genotype was unavailable. Hence, to acquire the actual prevalence of HCV genotypes, a cross-sectional study or survey consisting of samples from the whole nation is needed. However, the cost-effectiveness of this type of study is controversial.

CONCLUSION

In conclusion, over the past ten years, the construction of HCV genotypes has changed steadily. As various implementations were put into practice, G1 and G2 consistently decreased, and G3 and G6 became new challenges for the moment, particularly G3b. The two genotypes are mainly associated with IDUs. We should focus on the management of this population in the future regarding prevention and therapy to achieve the goal of WHO elimination in 2030.

ARTICLE HIGHLIGHTS

Research background

Hepatitis C virus (HCV) infection remains a major problem worldwide since the infected population and new infections have not decreased much. Direct-acting antiviral, a revolutionary regimen to cure HCV, is highly effective except for some special genotypes. Genotype distribution has undergone great changes since the transformation of the route of transmission. Thus, being aware of the HCV genotype distribution is definitely helpful in HCV infection management.

Research motivation

HCV includes a variety of genotypes owing to different transmission routes in different risk populations. Although the pangenotype regimen has become the best solution to cure HCV currently, not all genotypes respond well. To better curb HCV infection and reduce the disease and economic burden of HCV infection, knowing the present genotype constitution would be quite helpful.

Research objectives

Our main objective was to describe the distribution of HCV genotypes in China over the past ten years and to determine the trends of distribution in the future to better manage HCV infection.

Research methods

We searched all of the literature published in five electronic databases over the past 10 years. Then, we carefully selected literature that fulfilled our inclusion criteria and excluded literature that conformed to the exclusion criteria. After screening, the data of the remaining studies were extracted to build a database. Data were totaled and calculated according to different classifications: Regions, time periods, routes of transmission, and sexes.

Research results

A total of 76110 samples from 30 provinces were included in the study. Genotype 1 (G1) accounted for 58.2% nationwide, followed by G2, G6, G3b, and G3a. The constitution of genotypes varied among different regions. G6 and G3b were more common in the south and southwest (28.1%, 15.4%). The past ten years have witnessed a decrease in G1 and G2 and an increase in G3 and G6 in almost all regions.

The drug-user population had the most abundant genotypes, with G6 ranking first (33.3%), followed by G1 and G3b (23.4%, 18.5%).

Research conclusions

However, G1 and G2 accounted for the majority of HCV infections, and their decreasing tendency was clear and definite. G3 and G6 posed a new challenge in HCV infection. This study revealed the distribution of HCV genotypes in China over the past 10 years, providing information for HCV management strategies.

Research perspectives

How to curb the development of new HCV infections and effectively cure already infected populations should be investigated in the future.

FOOTNOTES

Author contributions: Yang J performed the research, analyzed the data, drew some of the figures and wrote the paper; Liu HX and Su YY designed the research; Liang ZS drew some of the pictures; Rao HY and Liu HX supervised the whole research, such as the design of the methodology, validation, review and editing of the paper.

Conflict-of-interest statement: All of the authors declare no conflicts of interest regarding the work in this paper. The authors declare no study sponsor involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for publication.

PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Jia yang 0000-0003-0516-6854; Hui-Xin Liu 0000-0003-1305-1977; Ying-Ying Su 0000-0003-3883-357X; Zhi-Sheng Liang 0000-0002-8155-9900; Hui-Ying Rao 0000-0003-2431-3872.

S-Editor: Fan JR

L-Editor: A

P-Editor: Fan JR

REFERENCES

- 1 **World Health Organization.** Global Hepatitis Report 2017.2017. [cited 29 May 2021]. Available from: <https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en.pdf>
- 2 **Chinese Society of Hepatology;** Chinese Society of Infectious Diseases; Chinese Medical Association. [Guidelines for the prevention and treatment of hepatitis C (2019 version)]. *Zhonghua Gan Zang Bing Za Zhi* 2019; **27**: 962-979 [PMID: 31941258 DOI: 10.3760/cma.j.issn.1007-3418.2019.12.008]
- 3 **Du G,** Li X, Musa TH, Ji Y, Wu B, He Y, Ni Q, Su L, Li W, Ge Y. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. *J Med Virol* 2019; **91**: 401-410 [PMID: 30192393 DOI: 10.1002/jmv.25311]
- 4 **Sarin SK,** Kumar M. Natural history of HCV infection. *Hepatology* 2012; **6**: 684-695 [PMID: 26201520 DOI: 10.1007/s12072-012-9355-6]
- 5 **World Health Organization.** Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.2018. [cited 29 May 2021]. Available from: <https://www.who.int/publications/i/item/9789241550345.pdf>
- 6 **Smith DB,** Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* 2014; **59**: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
- 7 **Keikha M,** Eslami M, Yousefi B, Ali-Hassanzadeh M, Kamali A, Yousefi M, Karbalaee M. HCV genotypes and their determinative role in hepatitis C treatment. *Virusdisease* 2020; **31**: 235-240 [PMID: 32904762 DOI: 10.1007/s13337-020-00592-0]
- 8 **Wu N,** Rao HY, Yang WB, Gao ZL, Yang RF, Fei R, Gao YH, Jin Q, Wei L. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. *Chin Med J (Engl)* 2020; **133**: 253-261 [PMID: 31934936 DOI: 10.1097/CM9.0000000000000629]
- 9 **Namayandeh M,** Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus

- genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. *Microbiol Immunol* 2020; **64**: 762-767 [PMID: [32902892](#) DOI: [10.1111/1348-0421.12845](#)]
- 10 **Grimaldi E**, Della Pepa ME, Martora F, Magliocca P, Iovene MR, Coppola N, Donnarumma G, Galdiero M. Distribution of Hepatitis C Virus Genotypes and Subtypes in the Metropolitan Area of Naples, Italy, in the Era of Interferon-Free Regimens. *Intervirology* 2017; **60**: 82-89 [PMID: [29161710](#) DOI: [10.1159/000481821](#)]
 - 11 **Zein NN**. Clinical significance of hepatitis C virus genotypes. *Clin Microbiol Rev* 2000; **13**: 223-235 [PMID: [10755999](#) DOI: [10.1128/CMR.13.2.223](#)]
 - 12 **Huang K**, Chen J, Xu R, Jiang X, Ma X, Jia M, Wang M, Huang J, Liao Q, Shan Z, Dailey C, Song X, Lu L, Li C, Rong X, Zhang M, Fu Y. Molecular evolution of hepatitis C virus in China: A nationwide study. *Virology* 2018; **516**: 210-218 [PMID: [29407379](#) DOI: [10.1016/j.virol.2018.01.015](#)]
 - 13 **Chen Y**, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. *Emerg Microbes Infect* 2017; **6**: e95 [PMID: [29089588](#) DOI: [10.1038/emi.2017.77](#)]
 - 14 **Rao H**, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Lu L, Jia J, Zhuang H. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol* 2014; **29**: 545-553 [PMID: [24090188](#) DOI: [10.1111/jgh.12398](#)]
 - 15 **Nie HM**, Chen JJ, Wang R, Wang CB, Dong HL, Chen YY. [Genotypes distribution of hepatitis C virus through multi-center, large sample studies among chronic hepatitis C patients in Chinese Han population]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2012; **33**: 501-504 [PMID: [22883178](#)]
 - 16 **Zhang Y**, Chen LM, He M. Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. *Viral J* 2017; **14**: 41 [PMID: [28231805](#) DOI: [10.1186/s12985-017-0710-z](#)]
 - 17 **Cai Q**, Zhao Z, Liu Y, Shao X, Gao Z. Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. *Int J Mol Med* 2013; **31**: 347-352 [PMID: [23241873](#) DOI: [10.3892/ijmm.2012.1209](#)]
 - 18 **Simmonds P**, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. *J Gen Virol* 1994; **75** (Pt 5): 1053-1061 [PMID: [8176367](#) DOI: [10.1099/0022-1317-75-5-1053](#)]
 - 19 **Wei L**, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. *Lancet Gastroenterol Hepatol* 2019; **4**: 127-134 [PMID: [30555048](#) DOI: [10.1016/S2468-1253\(18\)30343-1](#)]
 - 20 **Grebely J**, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim AY, McGovern BH, Schinkel J, George J, Shoukry NH, Lauer GM, Maher L, Lloyd AR, Hellard M, Dore GJ, Prins M; InC3 Study Group. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology* 2014; **59**: 109-120 [PMID: [23908124](#) DOI: [10.1002/hep.26639](#)]
 - 21 **Nkontchou G**, Zioli M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaute E, Baghdad I, Beaugrand M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. *J Viral Hepat* 2011; **18**: e516-e522 [PMID: [21914071](#) DOI: [10.1111/j.1365-2893.2011.01441.x](#)]
 - 22 **Bochud PY**, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A, Malinverni R, Francioli P, Negro F; Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *J Hepatol* 2009; **51**: 655-666 [PMID: [19665246](#) DOI: [10.1016/j.jhep.2009.05.016](#)]
 - 23 **Su YY**, Liu HX, Wang N. [Hepatitis C virus genotypes in China: a systematic review]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2013; **34**: 80-84 [PMID: [23648257](#)]
 - 24 **Jiang X**, Lv X, Chang L, Yan Y, Ji H, Sun H, Guo F, Rodgers MA, Yin P, Wang L. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors. *Antiviral Res* 2020; **181**: 104871 [PMID: [32717286](#) DOI: [10.1016/j.antiviral.2020.104871](#)]
 - 25 **Wang CB**, Cheng ZX, Chen JJ, Chen YY, Nie HM, Ling QH, Dong YN. Epidemiological characteristics and risk factors of hepatitis C virus genotype 1 infection: a national epidemiological survey of Chinese Han population. *Eur Rev Med Pharmacol Sci* 2016; **20**: 1052-1056 [PMID: [27049256](#)]
 - 26 **Peng J**, Lu Y, Liu W, Zhu Y, Yan X, Xu J, Wang X, Wang Y, Sun Z. Genotype Distribution and Molecular Epidemiology of Hepatitis C Virus in Hubei, Central China. *PLoS One* 2015; **10**: e0137059 [PMID: [26325070](#) DOI: [10.1371/journal.pone.0137059](#)]
 - 27 **Yan J**, Fu XB, Zhou PP, He X, Liu J, Huang XH, Yu GL, Yan XG, Li JR, Li Y, Lin P. Complicated HCV subtype expansion among drug users in Guangdong province, China. *Infect Genet Evol* 2019; **73**: 139-145 [PMID: [31048077](#) DOI: [10.1016/j.meegid.2019.04.031](#)]
 - 28 **Ju W**, Yang S, Feng S, Wang Q, Liu S, Xing H, Xie W, Zhu L, Cheng J. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. *Viral J* 2015; **12**: 109 [PMID: [26206422](#) DOI: [10.1186/s12985-015-0341-1](#)]
 - 29 **Dong ZX**, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, Gui HL, Zhao GD, Tang WL, Wang H, Xie Q. Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients' characteristics and clinical parameters. *J Dig Dis* 2012; **13**: 564-570 [PMID: [23107443](#) DOI: [10.1111/j.1751-2980.2012.00636.x](#)]
 - 30 **Fu Y**, Wang Y, Xia W, Pybus OG, Qin W, Lu L, Nelson K. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. *J Viral Hepat* 2011; **18**: 42-52 [PMID: [20196805](#) DOI: [10.1111/j.1365-2893.2010.01280.x](#)]
 - 31 **Wang M**, Liao Q, Xu R, Song D, Huang J, You Q, Shan Z, Huang K, Rong X, Fu Y. Hepatitis C virus 3b strains in

- injection drug users in Guangdong Province, China, may have originated in Yunnan Province. *Arch Virol* 2019; **164**: 1761-1770 [PMID: 31065852 DOI: 10.1007/s00705-019-04260-7]
- 32 **Rong X**, Xu R, Xiong H, Wang M, Huang K, Chen Q, Li C, Liao Q, Huang J, Xia W, Luo G, Ye X, Zhang M, Fu Y. Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011. *Arch Virol* 2014; **159**: 3231-3237 [PMID: 25085624 DOI: 10.1007/s00705-014-2185-1]
 - 33 **Chen F**, Zhang J, Guo F, Wen B, Luo S, Yuan D, Lin Y, Ou W, Tang P, Dai G, Li F, Liu W, Qu X. Hepatitis B, C, and D virus infection showing distinct patterns between injection drug users and the general population. *J Gastroenterol Hepatol* 2017; **32**: 515-520 [PMID: 27248508 DOI: 10.1111/jgh.13460]
 - 34 **Tao J**, Liang J, Zhang H, Pei L, Qian HZ, Chambers MC, Jiang Y, Xiao Y. The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. *PLoS One* 2015; **10**: e0140263 [PMID: 26466103 DOI: 10.1371/journal.pone.0140263]
 - 35 **Tian D**, Li L, Liu Y, Li H, Xu X, Li J. Different HCV genotype distributions of HIV-infected individuals in Henan and Guangxi, China. *PLoS One* 2012; **7**: e50343 [PMID: 23226265 DOI: 10.1371/journal.pone.0050343]
 - 36 **World Health Organization**. Accelerating access to hepatitis C diagnostics and treatment.2021. [cited 29 May 2021]. Available from: <https://www.who.int/publications/i/item/9789240027077.pdf>
 - 37 **Xia X**, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. *Public Health* 2008; **122**: 990-1003 [PMID: 18486955 DOI: 10.1016/j.puhe.2008.01.014]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

